FDA approves new treatments Dovato and lamiff for treatment of adult HIV-1 patients

recently, the United StatesThe FDA's(http://announced the approval of the new treatment dovato and lamivudine, which is expected to be the first twodrug(http://combination of drugs to treat HIV-1 infection, for the treatment of adult HIV-1 patients who have not previously received antiretroviral therapyDovato therapy is suitable for HIV-1 patients who are not known or presumed to be resistant to a single component of the drug, and in contrast to the standard three-drug combination therapy system, this new therapy provides patients with a combination of two drugs in a single pill, without the additional toxic effects and potential drug interactions of the third drugstudy
in a double-randomized, double-blind controlled clinicaltrial(http://, researchers studied 1,433 adult HIV-infected patients who had not received antiretroviral the virus to reveal the effectiveness and safety of taking Dovato dailyresearchers found that combining dolutweande and tinofovwe can reduce HIV levels in the blood of patients compared to the use of the drug doutwevir, enbutta, and tinofova, and that if patients can maintain HIV RNA in the blood for at least 48 weeks, the treatment is successful, with the most common adverse reactions in patients including headache, diarrhea, nausea, insomnia and fatigueBecause the drug doutwevir is associated with a known risk of neural tube defects, patients should not be treated with Dovato therapy from conception to three months of pregnancyDovato the warning on the box of the packaging (http:// box that patients infected with HIV and hepatitis B should treat the patient with hepatitis B or consider different combinations of drugs patients who take a double infection that contains lamiftine can have a certain tolerance, and the patient may also have severe liver problems, so close monitoring is required for patients with double infection stake with Dovato